Miltenyi Biotec GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Miltenyi Biotec GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10814
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Miltenyi Biotec GmbH (Miltenyi) is a biotechnology company that offers biomedical research and cellular therapy products for cell isolation, flow cytometry, sample preparation and cell culture. The company offers sample preparation, cell separation, flow cytometry, cell culture and stimulation, cell therapy, cell manufacturing, therapeutic apheresis, molecular and imaging products. Its cell separation products comprise cell separation reagents, cell separation instruments, columns, separators, and buffers and solutions. Miltenyi also offers instrument services, technical support, ordering and delivery and customized application services. The company operates in Germany, the US, the UK, France, Italy, Singapore, Japan, South Korea and others. Miltenyi is headquartered in Bergisch Gladbach, Germany.

Miltenyi Biotec GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Miltenyi Biotec GmbH, Medical Devices Deals, 2012 to YTD 2018 9
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Miltenyi Biotec Acquires Gene Therapy Assets from Lentigen 11
Venture Financing 12
Owl Biomedical Raises US$3 Million In Series A Financing 12
Partnerships 13
GlaxoSmithKline Enters into Agreement with Miltenyi Biotec 13
Cesca Therapeutics Enters into Distribution Agreement with Miltenyi Biotec 14
Applied Microarrays Enters Into Co-Development Agreement With Sensovation For FlexiPlex Array System 15
Licensing Agreements 16
Miltenyi Biotec Enters into Licensing Agreement with Genethon 16
Living Pharma Enters into Licensing Agreement with University of Maryland, Baltimore 17
Accellta Enters into Licensing Agreement with Miltenyi Biotec 18
Nanolek To Enter Into Licensing Agreement With Lentigen For Flu Vaccine 19
Asset Transactions 20
Miltenyi Biotec Acquires Gene Therapy Assets from Lentigen 20
Acquisition 21
Miltenyi Biotec Acquires LaVision BioTec 21
Lentigen Technology Acquires Living Pharma 22
Miltenyi Biotec Acquires Sensovation 23
Miltenyi Biotec Acquires Owl Biomedical, Disposable Cell Sorting Technology Provider 24
Miltenyi Biotec GmbH – Key Competitors 25
Miltenyi Biotec GmbH – Key Employees 26
Miltenyi Biotec GmbH – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Miltenyi Biotec GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
Miltenyi Biotec GmbH, Medical Devices Deals, 2012 to YTD 2018 9
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Miltenyi Biotec Acquires Gene Therapy Assets from Lentigen 11
Owl Biomedical Raises US$3 Million In Series A Financing 12
GlaxoSmithKline Enters into Agreement with Miltenyi Biotec 13
Cesca Therapeutics Enters into Distribution Agreement with Miltenyi Biotec 14
Applied Microarrays Enters Into Co-Development Agreement With Sensovation For FlexiPlex Array System 15
Miltenyi Biotec Enters into Licensing Agreement with Genethon 16
Living Pharma Enters into Licensing Agreement with University of Maryland, Baltimore 17
Accellta Enters into Licensing Agreement with Miltenyi Biotec 18
Nanolek To Enter Into Licensing Agreement With Lentigen For Flu Vaccine 19
Miltenyi Biotec Acquires Gene Therapy Assets from Lentigen 20
Miltenyi Biotec Acquires LaVision BioTec 21
Lentigen Technology Acquires Living Pharma 22
Miltenyi Biotec Acquires Sensovation 23
Miltenyi Biotec Acquires Owl Biomedical, Disposable Cell Sorting Technology Provider 24
Miltenyi Biotec GmbH, Key Competitors 25
Miltenyi Biotec GmbH, Key Employees 26
Miltenyi Biotec GmbH, Other Locations 27
Miltenyi Biotec GmbH, Subsidiaries 27

List of Figures
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Miltenyi Biotec GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Miltenyi Biotec GmbH, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Miltenyi Biotec GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PanOptica Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PanOptica Inc (PanOptica) is a clinical-stage biopharmaceutical company that develops topical eye drops for the treatment of sight-threatening eye diseases. The company concentrates on candidates that are at or near the investigational new drug application stage. It develops PAN-90806, a nov …
  • Corpak MedSystems Inc-医療機器分野:企業M&A・提携分析
    Summary Corpak MedSystems Inc (Corpak), a subsidiary of Halyard Health Inc is a medical device company that manufactures and markets enteral feeding safety devices. The company offers products such as cortrak systems, gastrostomy, nasoenteric systems, gastric decompression, NICU products and accesso …
  • Hokkaido Electric Power Co Inc:発電所・企業SWOT分析
    Hokkaido Electric Power Co Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on ke …
  • Asuragen Inc:医療機器:M&Aディール及び事業提携情報
    Summary Asuragen Inc (Asuragen) is an oncology molecular diagnostic company that provides laboratory medicine solutions. The company offers products such as amplidex, quantidex, and custom reagents. It provides custom and companion diagnostic services, which include commercialization, product approv …
  • Australian Gas Networks Ltd-エネルギー分野:企業M&A・提携分析
    Summary Australian Gas Networks Ltd (Australian Gas Networks) formerly Envestra Ltd, is an oil and gas company that distributes and transports natural gas. The company offers services such as managing the haulage of gas through each network, operation and maintenance of gas network, design an constr …
  • Sandvik AB:企業の戦略・SWOT・財務情報
    Sandvik AB - Strategy, SWOT and Corporate Finance Report Summary Sandvik AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Sakai Chemical Industry Co Ltd (4078):企業の財務・戦略的SWOT分析
    Sakai Chemical Industry Co Ltd (4078) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Menasha Corporation:企業の戦略・SWOT・財務分析
    Menasha Corporation - Strategy, SWOT and Corporate Finance Report Summary Menasha Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Modus Therapeutics Holding AB-製薬・医療分野:企業M&A・提携分析
    Summary Modus Therapeutics Holding AB (Modus), formerly known as Dilaforette Holding AB, is a biotechnology company that focuses on the development of sevuparin, a proprietary polysaccharide drug for the treatment of sickle cell disease (SCD). Modus Therapeutics Holding AB - Pharmaceuticals & Health …
  • SKC Co., Ltd. (011790):企業の財務・戦略的SWOT分析
    SKC Co., Ltd. (011790) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Seoul City Gas Co Ltd (017390):企業の財務・戦略的SWOT分析
    Seoul City Gas Co Ltd (017390) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Cooper-Standard Holdings Inc.:企業の戦略・SWOT・財務分析
    Cooper-Standard Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Cooper-Standard Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • XsunX Inc (XSNX):企業の財務・戦略的SWOT分析
    XsunX Inc (XSNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Mologic Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Mologic Ltd (Mologic) is a medical device company that designs, develops, manufactures and markets in vitro diagnostic medical devices. The company provides products such as bacterial vaginosis test kit, peritoneal dialysis test, lateral flow kit, desmosine ELISA kit and FMLP ELISA kit, amon …
  • Carl Zeiss AG:企業の戦略的SWOT分析
    Carl Zeiss AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Bauhaus International (Holdings) Limited (483):企業の財務・戦略的SWOT分析
    Bauhaus International (Holdings) Limited (483) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • X4 Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary X4 Pharmaceuticals Inc (X4 Pharma) is a pharmaceutical company that develops novel therapeutics to treat cancer and rare diseases. The company’s lead drug candidate, X4P-001-LD, is in Phase 2/3 trial used for the treatment for patients with WHIM and other immunodeficiency disease. It also de …
  • PAREXEL International Corporation:企業の戦略・SWOT・財務情報
    PAREXEL International Corporation - Strategy, SWOT and Corporate Finance Report Summary PAREXEL International Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Gammon Infrastructure Projects Ltd (GAMMNINFRA):企業の財務・戦略的SWOT分析
    Gammon Infrastructure Projects Ltd (GAMMNINFRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Optimum General Inc.:企業の戦略・SWOT・財務情報
    Optimum General Inc. - Strategy, SWOT and Corporate Finance Report Summary Optimum General Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆